messag report larg line though co tweak guidanc
detail noth new front either messag larg
cull earlier stage pipelin updat
increment one thing find interest continu invest cell therapi
manufactur viral vector manufactur build hous expertis gamma
lenti follow co near-term focu remain oncolog
note option remain open longer term pt increas
page analyst certif import disclosur
updat model reflect result decreas truvada
estim account generic off-set increas biktarvi estim net
pt increas
compani report filgotinib phase poc studi sjogren
disesas lupu meet primari endpoint
sourc compani report guggenheim secur llc estim
page analyst certif import disclosur
price target per share prev base dcf analysi forecast probability-weight revenu
expens assum discount rate termin growth rate
suscept risk appli entir biotech industri includ develop regulatori commerci manufactur
financ ip risk specif includ
commerci risk possibl may fail introduc new product market current product could produc less revenu
expect patient identif may slower expect product may receiv unfavor payor reimburs
clinic risk sever key pipelin product still clinic develop may delay clinic trial initi enrol
unexpect safeti issu efficaci lower expect
regulatori risk clinic trial ultim success possibl gild medicin approv global regulatori
agenc agenc may requir addit long-term data could delay potenti approv
ip risk depend intellectu properti protect control trade secret technolog innov inabl
defend patent could result increas gener competit addit compani may accus infring ip
current sever legal proceed relat product
competitor risk hiv hcv busi repres signific amount total product sale mix could face increas
competit aggress competit face signific competit therapi develop includ liver diseas
inflamm oncolog multipl compani develop therapi could prove better safeti efficaci
move faster market
page analyst certif import disclosur
mm except per share data
royalti contract revenu
factset consensu
total incom expens net
incom tax
net loss attribut non-controlling interest
net incom attribut
cog
sg
pre-tax adjustmentstax
non-gaap net incom attribut
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
